These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24533944)

  • 41. Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.
    Ando K; Oka M; Ohtake Y; Hayashishita M; Shimizu S; Hisanaga S; Iijima KM
    Biochem Biophys Res Commun; 2016 Sep; 478(2):929-34. PubMed ID: 27520376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry.
    Hruba L; Polishchuk P; Das V; Hajduch M; Dzubak P
    Biomed Pharmacother; 2022 Feb; 146():112549. PubMed ID: 34923338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long non-coding RNA 00507/miRNA-181c-5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer's disease.
    Yan Y; Yan H; Teng Y; Wang Q; Yang P; Zhang L; Cheng H; Fu S
    J Gene Med; 2020 Dec; 22(12):e3268. PubMed ID: 32891070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions.
    Kannanayakal TJ; Tao H; Vandre DD; Kuret J
    Acta Neuropathol; 2006 May; 111(5):413-21. PubMed ID: 16557393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclin-dependent kinase 5 immunoreactivity for granulovacuolar degeneration.
    Nakamori M; Takahashi T; Yamazaki Y; Kurashige T; Yamawaki T; Matsumoto M
    Neuroreport; 2012 Oct; 23(15):867-72. PubMed ID: 22968343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.
    Wu PR; Tsai PI; Chen GC; Chou HJ; Huang YP; Chen YH; Lin MY; Kimchi A; Chien CT; Chen RH
    Cell Death Differ; 2011 Sep; 18(9):1507-20. PubMed ID: 21311567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: Towards therapeutic management of Alzheimer's disease.
    Naqvi AAT; Jairajpuri DS; Noman OMA; Hussain A; Islam A; Ahmad F; Alajmi MF; Hassan MI
    J Biomol Struct Dyn; 2020 Aug; 38(13):3892-3907. PubMed ID: 31512980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain.
    Yang SD; Yu JS; Shiah SG; Huang JJ
    J Neurochem; 1994 Oct; 63(4):1416-25. PubMed ID: 7931292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levels of tau phosphorylation at different sites in Alzheimer disease brain.
    Ikura Y; Kudo T; Tanaka T; Tanii H; Grundke-Iqbal I; Iqbal K; Takeda M
    Neuroreport; 1998 Jul; 9(10):2375-9. PubMed ID: 9694231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
    An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
    Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ca2+/calmodulin-dependent protein kinase II promotes neurodegeneration caused by tau phosphorylated at Ser262/356 in a transgenic Drosophila model of tauopathy.
    Oka M; Fujisaki N; Maruko-Otake A; Ohtake Y; Shimizu S; Saito T; Hisanaga SI; Iijima KM; Ando K
    J Biochem; 2017 Nov; 162(5):335-342. PubMed ID: 28992057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tau protein kinase I/GSK-3 beta/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain.
    Song JS; Yang SD
    J Protein Chem; 1995 Feb; 14(2):95-105. PubMed ID: 7786411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of ribosomal protein S6 baseline phosphorylation and effect of tau pathology in the murine brain and human hippocampus.
    Klingebiel M; Dinekov M; Köhler C
    Brain Res; 2017 Mar; 1659():121-135. PubMed ID: 28119058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
    Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
    Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.
    Kimura T; Ono T; Takamatsu J; Yamamoto H; Ikegami K; Kondo A; Hasegawa M; Ihara Y; Miyamoto E; Miyakawa T
    Dementia; 1996; 7(4):177-81. PubMed ID: 8835879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration.
    Iijima-Ando K; Zhao L; Gatt A; Shenton C; Iijima K
    Hum Mol Genet; 2010 May; 19(10):1930-8. PubMed ID: 20159774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New patterns of intraneuronal accumulation of the microtubular binding domain of tau in granulovacuolar degeneration.
    Mena R; Robitaille Y; Cuello AC
    J Geriatr Psychiatry Neurol; 1992; 5(3):132-41. PubMed ID: 1323297
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.
    Griffin RJ; Moloney A; Kelliher M; Johnston JA; Ravid R; Dockery P; O'Connor R; O'Neill C
    J Neurochem; 2005 Apr; 93(1):105-17. PubMed ID: 15773910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.